uniQure (NASDAQ:QURE) CFO Sells $33,009.12 in Stock

uniQure (NASDAQ:QURE) CFO Christian Klemt sold 2,916 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $33,009.12. Following the sale, the chief financial officer now directly owns 155,168 shares of the company’s stock, valued at approximately $1,756,501.76. This represents a 1.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Christian Klemt also recently made the following trade(s):

• On Tuesday, February 25th, Christian Klemt sold 14,341 shares of uniQure stock. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70.
• On Monday, December 9th, Christian Klemt sold 1,796 shares of uniQure stock. The shares were sold at an average price of $7.55, for a total transaction of $13,559.80.

uniQure Stock Performance

Shares of QURE opened at $13.15 on Friday. The company’s fifty day moving average is $15.05 and its 200-day moving average is $9.79. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The firm has a market cap of $640.73 million, a price-to-earnings ratio of -2.65 and a beta of 0.38. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. HC Wainwright boosted their price target on shares of uniQure from $25.00 to $70.00 and gave the company a “buy” rating in a report on Monday, January 27th. Royal Bank of Canada restated an “outperform” rating and set a $24.00 price target on shares of uniQure in a report on Tuesday, January 21st. Mizuho boosted their price target on shares of uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, December 19th. The Goldman Sachs Group boosted their price target on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, December 12th. Finally, Cantor Fitzgerald boosted their price target on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, uniQure currently has an average rating of “Moderate Buy” and a consensus target price of $38.89.

Institutional Trading of uniQure

Large investors have recently modified their holdings of the company. RTW Investments LP acquired a new position in shares of uniQure in the 3rd quarter valued at $49,000. China Universal Asset Management Co. Ltd. increased its position in uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 3,663 shares in the last quarter. Atria Investments Inc acquired a new stake in uniQure in the 3rd quarter valued at about $53,000. Quarry LP acquired a new stake in uniQure in the 3rd quarter valued at about $58,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in uniQure in the 3rd quarter valued at about $69,000. 78.83% of the stock is owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.